The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

Simple Obesity Treatment by Single Intervention of Herbal Medicines without Ephedra Herba: A Case Report

마황을 포함하지 않은 한약처방 단일중재에 의한 단순비만 치료 : 증례보고

  • Received : 2019.11.25
  • Accepted : 2019.12.31
  • Published : 2019.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Glucagon-like peptide 1 (GLP-1), one of the gut peptide hormones, has an action to induce satiety, and its effect as an anti-obesity agent is known. Recently, it has been reported that many herbal medicines have an anti-diabetic effect through inhibition of DPP-4 enzyme and inducing of GLP-1 secretion. It is therefore suggested that GLP-1 may be effective for the treatment of obesity. In this study, we report a case of male obese patients treated with herbal medicine as a GLP-1 secretagogue. Methods: In this study, the patient took a fixed prescription of herbal medicine for 10 weeks and recorded his weight at each visit. Results: This prescription produced significant weight loss (BMI loss>5%). In the follow-up period after two weeks, the trend of weight loss was observed continuously. Conclusion: This prescription can be an alternative to ephedra herba-based obesity treatment.

Keywords

References

  1. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N EnglJ Med 2017;376(15):1492.
  2. Gonzalez-Muniesa P, Martinez-Gonzalez MA, Hu FB, Despres JP, Matsuzawa Y, Loos RJF, et al. Obesity. Nat Rev Dis Primers 2017;3:17034. https://doi.org/10.1038/nrdp.2017.34
  3. EBM-based Obesity KMCPG Development Committee (Korea Institute of Oriental Medicine, The Society of Korean Medicine for Obesity Research). KMCPG-Obesity. Daejeon Korea; Elsevier Korea: 2016.
  4. Jeong JW, Cho SW. Trend Research of the Human Body-Oriented Obesity Studies on Korean Medicine. Journal of Korean Medicine Rehabilitation 2016;26(1):49-61. https://doi.org/10.18325/jkmr.2016.26.1.49
  5. Song MY, Kim HJ, Lee MJ. The Safety Guidelines for use of Ma-huang in Obesity Treatment. Journal of Korean Oriental Association for Study of Obesity 2006;6(2):17-27.
  6. Jo GW, Ok JM, Kim SY, Lim YW. Review on the Efficacy and Safety of Mahuang and Epedrine in the Treatment of Obesity - Focused on RCT. J Korean Med 2018;38(3):170-84. https://doi.org/10.13048/jkm.17034
  7. Zell-Kanter M, Quigley MA, Leikin JB. Reduction in ephedra poisonings after FDA ban. N Engl J Med 2015;372(22):2172-4. https://doi.org/10.1056/NEJMc1502505
  8. Hallas J, Bjerrum L, Stovring H, Andersen M. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol 2008;168(8):966-73. https://doi.org/10.1093/aje/kwn191
  9. Liu Y, Sun M, Yao H, Liu Y, Gao R. Herbal Medicine for the Treatment of Obesity: An Overview of Scientific Evidence from 2007 to 2017. Evid Based Complement Alternat Med 2017;2017:8943059.
  10. Fu C, Jiang Y, Guo J, Su Z. Natural Products with Anti-obesity Effects and Different Mechanisms of Action. J Agric Food Chem 2016;64(51):9571-85. https://doi.org/10.1021/acs.jafc.6b04468
  11. Martel J, Ojcius DM, Chang CJ, Lin CS, Lu CC, Ko YF, et al. Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat Rev Endocrinol 2017;13(3):149-60. https://doi.org/10.1038/nrendo.2016.142
  12. Daneschvar HL, Aronson MD, Smetana GW. FDA-Approved Anti-Obesity Drugs in the United States. Am J Med 2016;129(8):879.
  13. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892
  14. Nuffer WA, Trujillo JM. Liraglutide: A New Option for the Treatment of Obesity. Pharmacotherapy 2015;35(10):926-34. https://doi.org/10.1002/phar.1639
  15. Zhen Z, Chang B, Li M, Lian FM, Chen L, Dong L, et al. Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats. Am J Chin Med 2011;39(1):53-63. https://doi.org/10.1142/S0192415X11008646
  16. Lian F, Li G, Chen X, Wang X, Piao C, Wang J, et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebocontrolled, multicenter trial. J Clin Endocrinol Metab 2014;99(2):648-55. https://doi.org/10.1210/jc.2013-3276
  17. Tong XL, Wu ST, Lian FM, Zhao M, Zhou SP, Chen XY, et al. The safety and effectiveness of TM81, a Chinese herbal medicine, in the treatment of type 2 diabetes: a randomized double-blind placebo-controlled trial. Diabetes Obes Metab 2013;15(5):448-54. https://doi.org/10.1111/dom.12051
  18. Yu Y, Hao G, Zhang Q, Hua W, Wang M, Zhou W, et al. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol 2015;97(2):173-7. https://doi.org/10.1016/j.bcp.2015.07.012
  19. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem 2009;24(5):1061-6. https://doi.org/10.1080/14756360802610761
  20. Gao Y, Zhang Z, Zhu J, Li B, Li Z, Zhu W, et al. Recent progress in natural products as DPP-4 inhibitors. Future Med Chem 2015;7(8):1079-89. https://doi.org/10.4155/fmc.15.49
  21. Sui Y, Zhao HL, Wong VC, Brown N, Li XL, Kwan AK, et al. A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. Obes Rev 2012;13(5):409-30. https://doi.org/10.1111/j.1467-789X.2011.00979.x
  22. Hasani-Ranjbar S, Jouyandeh Z, Abdollahi M. A systematic review of anti-obesity medicinal plants - an update. J Diabetes Metab Disord 2013;12(1):28. https://doi.org/10.1186/2251-6581-12-28
  23. Xu L, Zhao W, Wang D, Ma X. Chinese Medicine in the Battle Against Obesity and Metabolic Diseases. Front Physiol 2018;9:850. https://doi.org/10.3389/fphys.2018.00850
  24. Al-masri IM, Mohammad MK, Tahaa MO, Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem 2009;24(5):1061-6. https://doi.org/10.1080/14756360802610761
  25. Yu Y, Liu L, Wang X, Liu X, Liu X, Xie L, et al. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem Pharmacol 2010;79(7):1000-6. https://doi.org/10.1016/j.bcp.2009.11.017
  26. Zhang Y, Ding Y, Zhong X, Guo Q, Wang H, Gao J, et al. Geniposide acutely stimulates insulin secretion in pancreatic $\beta$-cells by regulating GLP-1 receptor/cAMP signaling and ion channels. Mol Cell Endocrinol 2016 Jul 15;430:89-96. https://doi.org/10.1016/j.mce.2016.04.020
  27. Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract 2014;68(5):557-67. https://doi.org/10.1111/ijcp.12361
  28. Xu L, Li Y, Dai Y, Peng J. Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms. Pharmacol Res 2018;130:451-65. https://doi.org/10.1016/j.phrs.2018.01.015
  29. Pang B, Yu XT, Zhou Q, Zhao TY, Wang H, Gu CJ, et al. Effect of Rhizoma coptidis (Huang Lian) on Treating Diabetes Mellitus. Evid Based Complement Alternat Med 2015;2015:921416.
  30. Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry 2019;24(1):18-33. https://doi.org/10.1038/s41380-018-0017-5
  31. Ren L, Chen G. Rapid antidepressant effects of Yueju: A new look at the function and mechanism of an old herbal medicine. J Ethnopharmacol 2017;203:226-32. https://doi.org/10.1016/j.jep.2017.03.042
  32. Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Int 2007;51(6-7):361-9. https://doi.org/10.1016/j.neuint.2007.04.021
  33. Zhang CY, Parton LE, Ye CP, Krauss S, Shen R, Lin CT, et al. Genipin inhibits UCP2-mediated proton leak and acutely reverses obesity- and high glucose-induced beta cell dysfunction in isolated pancreatic islets. Cell Metab 2006;3(6):417-27. https://doi.org/10.1016/j.cmet.2006.04.010
  34. Guan L, Gong D, Yang S, Shen N, Zhang S, Li Y, et al. Genipin ameliorates diet-induced obesity via promoting lipid mobilization and browning of white adipose tissue in rats. Phytother Res 2018;32(4):723-32. https://doi.org/10.1002/ptr.6022
  35. Shan M, Yu S, Yan H, Guo S, Xiao W, Wang Z, et al. A Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural Product. Molecules 2017;22(10):1689. https://doi.org/10.3390/molecules22101689
  36. Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol 2017;1:35. https://doi.org/10.1038/s41698-017-0038-6
  37. Kim J, Yang G, Kim Y, Kim J, Ha J. AMPK activators: mechanisms of action and physiological activities. Exp Mol Med 2016;48:224.
  38. Wang L, Ma R, Liu C, Liu H, Zhu R, Guo S, et al. Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases. Curr Pharm Des 2017;23(7):1077-97. https://doi.org/10.2174/1381612822666161010105242
  39. Camacho S, Michlig S, de Senarclens-Bezencon C, Meylan J, Meystre J, Pezzoli M, et al. Anti-obesity and anti-hyperglycemic effects of cinnamaldehyde via altered ghrelin secretion and functional impact on food intake and gastric emptying. Sci Rep 2015;5:7919. https://doi.org/10.1038/srep07919
  40. Zuo J, Zhao D, Yu N, Fang X, Mu Q, Ma Y, et al. Cinnamaldehyde Ameliorates Diet-Induced Obesity in Mice by Inducing Browning of White Adipose Tissue. Cell Physiol Biochem 2017;42(4):1514-25. https://doi.org/10.1159/000479268
  41. Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr 2014;5(4):404-17. https://doi.org/10.3945/an.113.005603
  42. Ye XP, Song CQ, Yuan P, Mao RG. $\alpha$ -Glucosidase and $\alpha$-Amylase Inhibitory Activity of Common Constituents from Traditional Chinese Medicine Used for Diabetes Mellitus. Chinese Journal of Natural Medicines 2010;8(5):349-52. https://doi.org/10.1016/S1875-5364(10)60041-6
  43. Seyedan A, Alshawsh MA, Alshagga MA, Koosha S, Mohamed Z. Medicinal Plants and Their Inhibitory Activities against Pancreatic Lipase: A Review. Evid Based Complement Alternat Med 2015;2015:973143.
  44. Hu J, Shi K, Meng Q. Mapping the knowledge of international Chinese medicines treatment on type 2 diabetes: A biblimetrical study. Journal of Traditional Chinese Medical Sciences 2016;3(4):263-72. https://doi.org/10.1016/j.jtcms.2016.12.002
  45. Thaiss CA, Itav S, Rothschild D, Meijer MT, Levy M, Moresi C, et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. Nature 2016 Dec 22;540(7634):544-51.
  46. van Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss - the role of adipose tissue. Nat Rev Endocrinol 2019 May;15(5):274-87. https://doi.org/10.1038/s41574-018-0148-4
  47. Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, et al. Structural Alteration of Gut Microbiota during the Ameliorationof Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. MBio 2018;9(3):e02392-17.
  48. Wei X, Tao J, Xiao S, Jiang S, Shang E1, Zhu Z, et al. Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gutmicrobiota. Sci Rep 2018;8(1):3685. https://doi.org/10.1038/s41598-018-22094-2